Kindeva

Kindeva Drug Delivery Invests in Second Manufacturing Line for Greener Inhalers at UK Manufacturing Site

Retrieved on: 
Montag, Mai 6, 2024
Biotechnology, Pharmaceutical, Other Manufacturing, Health, Medical Devices, Manufacturing, Clinical Trials, Other Health, European, HFA, Drug delivery, GWP, GMP, Kindeva, Isocyanate, Renewable energy

Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global Warming Potential) propellants in its Loughborough, U.K., facility.

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global Warming Potential) propellants in its Loughborough, U.K., facility.
  • Kindeva’s first pMDI manufacturing line, which was announced in 2022 , is in its installation phase and will be completed later in 2024.
  • This second investment in low-GWP GMP manufacturing capacity further underscores Kindeva’s commitment to enable the pharmaceutical industry to meet its sustainability goals, whilst ensuring patient choice is not compromised.
  • Phase down of the existing propellants will commence in 2027 in the EU and be completed by the end of 2029.

Denis Johnson Joins Kindeva Drug Delivery as Chief Operating Officer to Lead Global Operations

Retrieved on: 
Donnerstag, April 18, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Chemicals, Plastics, Manufacturing, Drug delivery, Administration, Johnson & Johnson, GWP, Kindeva, CDMO, Catalent, Patient, Multimedia, Teradyne, Biogen, Growth, Head, Pharmaceutical industry

Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced that Denis Johnson has joined the company as its new Chief Operating Officer (COO).

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced that Denis Johnson has joined the company as its new Chief Operating Officer (COO).
  • Denis joins Kindeva to lead global operations for all Kindeva’s state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.
  • Most recently, he served as Head of Global Manufacturing and Technical Operations at Biogen and held several leadership roles at Catalent, Boston Scientific, Teradyne, and Johnson & Johnson.
  • “I’m excited to join the Kindeva team to drive continued operational excellence and implement strategies that ensure the timely delivery of life-changing medications to patients worldwide.”

Kindeva Drug Delivery Launches New Analytical Services Global Business Unit

Retrieved on: 
Mittwoch, Januar 31, 2024
Research, Medical Devices, Packaging, Chemicals, Plastics, Clinical Trials, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, USP, Knowledge, CGMP, MD, Kindeva, ICH, Safety, CCI, Syringe, False vacuum decay, Drug delivery, Guideline, GMP, Fine chemical

Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, announced the expansion of its analytical services capabilities — launching a new global business unit offering integrated and stand-alone analytical support to the wider pharmaceutical, biopharmaceutical, and medical device sector.

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, announced the expansion of its analytical services capabilities — launching a new global business unit offering integrated and stand-alone analytical support to the wider pharmaceutical, biopharmaceutical, and medical device sector.
  • For more than half a century, Kindeva has developed significant knowledge, experience, and expertise working on inhaled, injectable, and transdermal drug delivery development programs and cGMP commercial supply.
  • Additionally, Kindeva has built deep expertise and capability in cGMP analytical services supporting its product development and supply partners.
  • In addition to increasing Kindeva’s global analytical footprint, Kindeva’s recently opened 32,000-square-foot state-of-the-art laboratories in Woodbury, Minnesota, will serve as the central hub for its expanded suite of stand-alone analytical services.

Kindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) Announce Collaboration for Low GWP Propellant Conversion

Retrieved on: 
Dienstag, Dezember 5, 2023
Other Manufacturing, Medical Devices, Medical Supplies, Chemicals, Plastics, Manufacturing, Other Health, Health, Pharmaceutical, General Health, Carbon, CDMO, Lung, DDL, Patient, Isocyanate, European, GWP, BMV, Pulmonary drug delivery, National Highway 152A (India), Partnership, Metered-dose inhaler, Drug delivery, Pharmaceutical industry, Engineered wood, Kindeva

Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation , S.A.B.

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation , S.A.B.
  • de C.V. (BMV: ORBIA*) Fluorinated Solutions business ( Koura ®), a global leader in the development, manufacture, and supply of fluoroproducts and technologies, announced today a co-development collaboration for the conversion from existing marketed pressurised Metered Dose Inhaler (pMDI) products to Koura’s more sustainable and environmentally-conscious medical propellant; HFA 152a, known as Zephex® 152a.
  • View the full release here: https://www.businesswire.com/news/home/20231205198764/en/
    This strategic collaboration will focus on accelerating the conversion of existing marketed pMDI inhaler products to low global warming potential (GWP) pMDIs utilizing Koura’s Zephex 152a platform with the objective of reducing respiratory healthcare carbon emissions while safeguarding patient choice.
  • This partnership aims to facilitate conversion of pMDI products to the lower GWP propellent 152a and progressing them through clinical development.

Meridian Medical Technologies, Kindeva Drug Delivery’s Global Health Security Division, Awarded Contract to Supply DuoDote®

Retrieved on: 
Dienstag, November 14, 2023
Medical Devices, Other Defense, Medical Supplies, Contracts, Chemicals, Plastics, Manufacturing, Health, Pharmaceutical, Defense, Health technology, Head, ASPR, Emergency, Meridian Medical Technologies, FDA, Infection, Antidote, Kindeva, Human services, Pralidoxime, Atropine, Administration, Hospital, CBRN, Meridian

Meridian Medical Technologies, LLC (Meridian), a division of Kindeva Drug Delivery (Kindeva), has been awarded a $9.9M contract to supply DuoDote® to the Administration for Strategic Preparedness and Response (ASPR) within the United States (U.S.) Department of Health and Human Services.

Key Points: 
  • Meridian Medical Technologies, LLC (Meridian), a division of Kindeva Drug Delivery (Kindeva), has been awarded a $9.9M contract to supply DuoDote® to the Administration for Strategic Preparedness and Response (ASPR) within the United States (U.S.) Department of Health and Human Services.
  • Meridian is a globally leading health security and chemical, biological, radiological, and nuclear (CBRN) medical countermeasure provider.
  • Meridian supplies DuoDote® to U.S. and allied ministries of health and defense, as well as hospitals and civilian first responder agencies.
  • “Meridian has a decades long history of providing medical countermeasures to military and public health agencies and civilian responders globally.

Kindeva Drug Delivery Appoints Brian Schubmehl as Chief Human Resources Officer

Retrieved on: 
Freitag, September 15, 2023
Biotechnology, Pharmaceutical, Human Resources, Health, Packaging, Medical Devices, Professional Services, Manufacturing, HR, Workforce, Kindeva, CDMO, Acquisition, Drug delivery, Multimedia, Culture, Whirlpool Corporation, Management

Kindeva Drug Delivery (Kindeva), a premier global drug delivery device contract development and manufacturing organization (CDMO), announced that Brian Schubmehl has joined the company as Chief Human Resources Officer.

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a premier global drug delivery device contract development and manufacturing organization (CDMO), announced that Brian Schubmehl has joined the company as Chief Human Resources Officer.
  • View the full release here: https://www.businesswire.com/news/home/20230915824136/en/
    Brian Schubmehl joins Kindeva Drug Delivery as Chief Human Resources Officer.
  • Before joining Kindeva, Brian was Vice President, Global Human Resources at Curia, where he steered expansion from 1,500 to 3,700 employees and developed key strategies that enabled organizational success.
  • “As Chief Human Resources Officer, his expertise and leadership will expand and safeguard Kindeva’s strengths as we continue to grow our organization as a global force in combination drug delivery.”

U.K. Government Grant Unlocks £33M Investment With Kindeva Drug Delivery for Greener Inhaler Future

Retrieved on: 
Donnerstag, August 3, 2023
Research, Pharmaceutical, Medical Devices, Environment, Clinical Trials, Science, Chemicals, Plastics, Biotechnology, Medical Supplies, Climate Change, Health, Other Science, Manufacturing, GWP, Government, CDMO, Drug delivery, Patient, Pharmaceutical industry, Kindeva

Kindeva Drug Delivery (Kindeva), a premier global drug delivery device contract development and manufacturing organization (CDMO), announced that the company has received a grant from the U.K. Government’s Life Sciences Innovation Manufacturing Fund (LSIMF) , unlocking a £33 million investment with Kindeva toward enhancing inhaler manufacturing and sustainability.

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a premier global drug delivery device contract development and manufacturing organization (CDMO), announced that the company has received a grant from the U.K. Government’s Life Sciences Innovation Manufacturing Fund (LSIMF) , unlocking a £33 million investment with Kindeva toward enhancing inhaler manufacturing and sustainability.
  • The joint funds enhance Kindeva’s capability and capacity to manufacture the next generation of green pressurized metered-dose inhalers (pMDIs) and to continue delivering ever-evolving therapies for respiratory diseases worldwide.
  • “This joint investment of public and private funds creates myriad new opportunities for Kindeva colleagues within the U.K., as significant technical and regulatory expertise is required in the development and manufacturing of complex inhalation products,” said Kindeva Global Chief Commercial Officer David Stevens .
  • Additionally, this industry and government investment supports:
    The U.K. grant is the sixth investment through the LSIMF, which has supported U.K. life sciences manufacturing with £340 million in joint government and industry backing in the last financial year.

Kindeva Drug Delivery Announces the Appointment of David Stevens as Global CCO

Retrieved on: 
Mittwoch, April 5, 2023
Science, Other Science, Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Other Health, GMP, Charles River Laboratories, University, Drug delivery, Marketing, MBA, Research, Multimedia, CCO, CDMO, Patient, Recipharm, Growth, AMRI, Fine chemical, Kindeva

Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, announced that David Stevens has joined the organization as global chief commercial officer (CCO).

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, announced that David Stevens has joined the organization as global chief commercial officer (CCO).
  • Stevens will spearhead the commercial, business development, and research and development activities for the business to ensure continued growth, expansion, and innovation.
  • View the full release here: https://www.businesswire.com/news/home/20230405005276/en/
    David Stevens has been appointed global chief commercial officer for Kindeva Drug Delivery.
  • “The Kindeva organization has a strong history of achievement, expertise, and the infrastructure to handle an extensive range of critical complex drug delivery challenges,” Stevens said.

Kindeva and Meridian Combine: Create Leading Drug-Device Combination Product CDMO

Retrieved on: 
Montag, Dezember 12, 2022
Biotechnology, Pharmaceutical, Health, Medical Devices, 3M, Inhalation, Pfizer, CDMO, JPMorgan Chase, Chase Bank, Health technology, Drug delivery, Research, NYSE, Kirkland & Ellis, Multimedia, Administration, PFE, Meridian Medical Technologies Inc., Pharmaceutical industry, Meridian, Kindeva

Kindeva Drug Delivery (Kindeva) and Meridian Medical Technologies (Meridian) announced today the completion of the transaction to combine the two companies.

Key Points: 
  • Kindeva Drug Delivery (Kindeva) and Meridian Medical Technologies (Meridian) announced today the completion of the transaction to combine the two companies.
  • The combination has created a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products.
  • The combination will operate under the Kindeva name, with Meridian operating as, Meridian Medical Technologies, a Kindeva Company.
  • The combination of Kindeva and Meridian creates a clear market leader in the drug-device CDMO sector.